SABCS 2022
Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Your search for esrd returned 2 results
SABCS 2022
Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
